155 / 172
155
94. Knevel R, Schoels M, Huizinga TW, Aletaha D, Burmester
GR, Combe B, et al. Current evidence for a strategic approach
to the management of rheumatoid arthritis with disease-
modifying antirheumatic drugs: a systematic literature review
informing the EULAR recommendations for the management
of rheumatoid arthritis. Ann Rheum Dis 2010;69:987-94.
95. Katchamart W, Trudeau J, Phumethum V, Bombardier C.
Methotrexate monotherapy versus methotrexate combination
therapy with non-biologic disease modifying anti-rheumatic
drugs for rheumatoid arthritis. Cochrane Database Syst Rev
201014;(4):CD008495.
96. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-
Reino JJ, et al. Comparison of tocilizumab monotherapy versus
methotrexate monotherapy in patients with moderate to
severe rheumatoid arthritis: the AMBITION study. Ann
Rheum Dis 2010;69:88-96.
97. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens
AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with
methotrexate in early rheumatoid arthritis: aiming for
remission. Computer Assisted Management in Early
Rheumatoid Arthritis (CAMERA, an open-label strategy trial).
Ann Rheum Dis 2007;66:1443-9.
98. Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R.
A 36 month comparative trial of methotrexate and gold
sodium thiomalate in the treatment of early active and erosive
rheumatoid arthritis. Br J Rheumatol 1998; 37: 1060-8.
99. Luis M, Pacheco-Tena C, Cazarín-Barrientos J, Lino-Pérez
L, Goycochea MV, Vazquez-Mellado J, et al. Comparison of
two schedules for administering oral low-dose methotrexate
(weekly versus every-other-week) in patients with rheumatoid
arthritis in remission: a twenty-four week, single blind,
randomized study. Arthritis Rheum 1999;42:2160-5.
100. Svensson B, Schaufelberger C, Teleman A, Theander J.
Remission and response to early treatment of RA assessed by